Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Brazg

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of Diabetes Science and Technology|February 10, 2011
FreeStyle Navigator Continuous Glucose Monitoring System with TRUstart algorithm, a 1-hour warm-up timeMcGarraugh Geoffrey, Ronald Brazg, Weinstein Richard
Diabetes Technology & Therapeutics|November 25, 2003
A continuous glucose sensor based on wired enzyme technology -- results from a 3-day trial in patients with type 1 diabetesBen Feldman, Ronald Brazg, Sherwyn Schwartz, et al.
Clinical Therapeutics|December 13, 2006
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyJulio Rosenstock, Ronald Brazg, Paula J Andryuk, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 6, 2023
Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring SystemShridhara Alva, Ronald Brazg, Kristin Castorino, et al.
Diabetes Technology & Therapeutics|September 17, 2020
Performance of an Automated Insulin Delivery System: Results of Early Phase Feasibility StudiesMark Christiansen, Amy Bartee, Amy Lalonde, et al.
Diabetes Technology & Therapeutics|May 12, 2025
Safety and Functionality of a Novel Clinical Decision-Support Algorithm with Insulin Efsitora Alfa in Adults with Type 2 Diabetes: Early Feasibility StudyMichelle Katz, Christof Kazda, Jie Xue, et al.
Clinical Cardiology|April 11, 2003
A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatinDonald B Hunninghake, Mark E McGovern, Michael Koren, et al.
Diabetes Technology & Therapeutics|April 25, 2014
Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensorTimothy S Bailey, Andrew Ahmann, Ronald Brazg, et al.
Diabetes Technology & Therapeutics|November 18, 2017
The Effect of Prior Continuous Glucose Monitoring Use on Glycemic Outcomes in the Pivotal Trial of the MiniMed<sup>™</sup> 670G Hybrid Closed-Loop SystemToni L Cordero, Satish K Garg, Ronald Brazg, et al.
Journal of Diabetes Science and Technology|April 4, 2025
Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor DesignShridhara Alva, Anuj Bhargava, Bruce Bode, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Diabetes Science and Technology|February 10, 2011
FreeStyle Navigator Continuous Glucose Monitoring System with TRUstart algorithm, a 1-hour warm-up timeMcGarraugh Geoffrey, Ronald Brazg, Weinstein Richard
Diabetes Technology & Therapeutics|November 25, 2003
A continuous glucose sensor based on wired enzyme technology -- results from a 3-day trial in patients with type 1 diabetesBen Feldman, Ronald Brazg, Sherwyn Schwartz, et al.
Clinical Therapeutics|December 13, 2006
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyJulio Rosenstock, Ronald Brazg, Paula J Andryuk, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 6, 2023
Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring SystemShridhara Alva, Ronald Brazg, Kristin Castorino, et al.
Diabetes Technology & Therapeutics|September 17, 2020
Performance of an Automated Insulin Delivery System: Results of Early Phase Feasibility StudiesMark Christiansen, Amy Bartee, Amy Lalonde, et al.
Diabetes Technology & Therapeutics|May 12, 2025
Safety and Functionality of a Novel Clinical Decision-Support Algorithm with Insulin Efsitora Alfa in Adults with Type 2 Diabetes: Early Feasibility StudyMichelle Katz, Christof Kazda, Jie Xue, et al.
Clinical Cardiology|April 11, 2003
A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatinDonald B Hunninghake, Mark E McGovern, Michael Koren, et al.
Diabetes Technology & Therapeutics|April 25, 2014
Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensorTimothy S Bailey, Andrew Ahmann, Ronald Brazg, et al.
Diabetes Technology & Therapeutics|November 18, 2017
The Effect of Prior Continuous Glucose Monitoring Use on Glycemic Outcomes in the Pivotal Trial of the MiniMed<sup>™</sup> 670G Hybrid Closed-Loop SystemToni L Cordero, Satish K Garg, Ronald Brazg, et al.
Journal of Diabetes Science and Technology|April 4, 2025
Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor DesignShridhara Alva, Anuj Bhargava, Bruce Bode, et al.
Pageof 2